Nuformix PLC Result of General Meeting (1561A)

TIDMNFX

RNS Number : 1561A

Nuformix PLC

31 January 2022

Nuformix plc

("Nuformix" or the "Company")

Result of General Meeting

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, confirms that, further to the announcement made in connection with the Subscription to raise GBP1.65 million with Lanstead Capital Investors L.P., at the General Meeting held earlier today all Resolutions were passed by way of a poll, the full results of which are given below:

 
               Resolution             Ordinary/      For                 Against            Total votes 
                                       Special                                                  cast 
                                                    No. of       %       No. of       % 
                                                     votes                votes 
     THAT, in addition 
      to existing authorities, 
      the directors are 
      authorised to exercise 
      all powers of the 
      Company to allot 
 1    new ordinary shares             Ordinary    81,448,911   95.22%   4,093,030   4.78%   85,541,941 
     THAT, upon the passing 
      of Resolution 1, 
      the Directors be 
      empowered to allot 
      new ordinary shares 
      for cash on a non-pre-emptive 
 2    basis.                           Special    81,438,942   95.19%   4,116,235   4.81%   85,555,177 
 

Accordingly, the Company now has sufficient authorities in place to allot the Second Subscription Shares and the Second Value Payment Shares. The Second Subscription remains conditional on there being no requirement for the Company to publish a prospectus in connection with the Second Subscription. It is expected that the Second Subscription Shares and the Second Value Payment Shares will be issued in April 2022 and at that point application will be made to the London Stock Exchange and the Financial Conduct Authority for Admission.

Notes:

1. Any proxy arrangement which gave discretion to the Chairman has been included in the "for" totals.

2. A "Vote withheld" is not a vote in law and is not counted in the calculation of the percentage of shares voted "For" or "Against" any resolution.

3. The number of shares in issue at close of business on 28 January 2022 was 615,609,368. The Company does not hold any shares in treasury.

Unless otherwise defined, all capitalised terms used but not defined in this announcement shall have the meaning given to them in the Circular dated 14 January 2022, a copy of which is available to view on the Company's website ( www.nuformix.com ).

Enquiries:

 
 Nuformix plc                                                               via Walbrook 
 Dr Alastair Riddell, Executive 
  Chairman 
 
 Allenby Capital Limited                                            [phone] 
 Nick Athanas / George Payne (Corporate 
  Finance) 
 Stefano Aquilino / Matt Butlin (Sales 
  and Corporate Broking) 
 
 Walbrook PR                              [e-mail] or [phone] 
 Anna Dunphy / Phillip Marriage                   Tel: [phone] 
                                                                                 984 082 
 
 

About Nuformix

Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has an early-stage pipeline of preclinical and Phase I-ready assets with potential for significant value and early licensing opportunities.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ROMGZGFMMMMGZZM

(END) Dow Jones Newswires

January 31, 2022 06:04 ET (11:04 GMT)